Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P18545
UPID:
CNRG_HUMAN
Alternative names:
-
Alternative UPACC:
P18545; Q3KP63; Q7Z3U8
Background:
The Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma plays a pivotal role in the visual signal transduction pathway. It is essential for the processes of transmission and amplification of the visual signal, acting as an effector molecule in G-protein-mediated phototransduction in vertebrate rods and cones.
Therapeutic significance:
Given its crucial role in vision, mutations affecting this protein are directly linked to Retinitis pigmentosa 57, a progressive retinal dystrophy. Understanding the role of this protein could pave the way for innovative treatments for this and potentially other related visual disorders.